健康元

健康元

News
Group real-time dynamics and cutting-edge information in the field of One Health
img
Your location：
Homepage
/
News
img
The Inhale Preparation of Joincare is Listed in the Guideline for Diagnosis and Management of Chronic Obstructive Pulmonary Disease Time Posted：2021-03-16 16:51:35
The Guideline for Diagnosis and Management of Chronic Obstructive Pulmonary Disease in 2001 (‘the new guideline’ in the following passages) has been released recently. Lishutong (Levosalbutamol Hydrocloride Nebuliser Solution), a product Joincare Pharmaceutical Group Industry Co., Ltd (Joincare), is the first authorized β2 adrenoceptor agonist. The medicine was recommended as the first-line treatment. All of these is a sign that the high-standard inhale preparation formally join in the market competition.
More
img
Exploring the Blue Ocean Market of Inhalation Industry！Two Major Products Developed by Joincare Were Permitted to Produce Time Posted：2020-08-31 14:48:38
In the evening of 24th, Aug., Joincare Pharmaceutical Group Industry Co., Ltd (Joincare) has released the public notification that the company gained the ‘Drug Production License’ (DPL). Until now, the two major combination medicinal products developed by Joincare, Compound Ipratropium Bromide Solution for Inhalation and Levosalbutamol Hydrochloride Nebuliser Solution, have begun to be manufactured.
More
Budesonide Suspension (Big Specification) Approved, Joincare Establishes Inhalable Drug Matrix Time Posted：2020-12-11 20:00:29
News from Cailian Press (Shenzhen, Reporter: Ding Rong): Joincare Pharmaceutical Group Industry Co., Ltd. (Joincare, 600380.SH) has seen new progress in its high-profile Budesonide Suspension for Inhalation. The Company recently received the Drug Registration Certificate issued by the National Medical Products Administration (NMPA) for its drug named Budesonide Suspension for Inhalation (generic name), according to the announcement released by Joincare on the evening of December 10. A number of the Company's inhalable drugs have been approved, and this Budesonide Suspension for Inhalation (big specification) is projected to be a core product with a large market volume in line with its deployment at the early stage, a manager from Joincare told Cailian Press on the morning of December 11.
More
Action Speaks for Responsibility, Joincare Wins Best Social Responsibility Award of "China ESG Golden Awards 2020" Time Posted：2020-12-10 19:01:21
The "Environment, Social Responsibility and Corporate Governance (ESG) Summit of Sina Golden Kirin Forum 2020", sponsored by finance.sina.com.cn, was held in the building of the Sina headquarters in Beijing on December 8. Under the theme of "Implementing an ESG Philosophy to Achieve the Sustainable Development Goals", this summit invited a number of excellent listed companies, institutional investors and authoritative media to bring together upstream and downstream resources of industrial development, connect ideas and resources, and unleash value and strength.  
More
Giving full play to the advantages of pharmaceutical health industry, Joincare has been awarded “Outstanding Contribution Award of Anti-epidemic” Time Posted：2020-11-17 20:22:35
On November 16, “the Best Listed Companies in Greater China in 2020” award ceremony hosted by Gelonghui was grandly held in Chengdu. Through screening layer by layer, Joincare Pharmaceutical Group Industry Co., Ltd. won “Outstanding Contribution Award of Anti-epidemic” from many candidate enterprises.
More
Joincare (600380.SH): Meropenem for injection has passed the generic drug consistency evaluation Time Posted：2020-10-27 20:16:02
Gelonghui October 23 | Joincare (600380.SH) published that, recently, Shenzhen Haibin Pharmaceutical Co. Ltd. (hereinafter referred to as Shenzhen Haibin), the wholly-owned subsidiary of the Company, has received the Notice of Approval of Supplementary Drug Application approved and issued by National Medical Products Administration, that meropenem for injection produced by Shenzhen Haibin has passed the consistency evaluation of quality and curative effect of generic drug.
More
The fifth session of Pengcheng Charitable Donation List was published, and Joincare’s Chairman Zhu Baoguo was selected into the personal list of charitable donation Time Posted：2020-09-23 20:24:40
In the morning of September 19, on the eighth session of the exchange and exhibition meeting of Chinese public charity projects, “the Fifth Session of Pengcheng Charity Award and 2019 Shenzhen Charitable Donation List Release Conference” was held in Meihua Hall of Shenzhen Convention & Exhibition Center grandly. 119 persons, enterprises, institutions and projects won this award. Zhu Baoguo, Chairman of Joincare Pharmaceutical Group Industry Co., Ltd., once again selected into “Pengcheng Charitable Donation Personal List” of Shenzhen Pengcheng Charitable Award due to his outstanding contributions in the field of public charities.
More
Joincare leads the breathing layout and releases intrinsic value, many institutions are optimistic about its future Time Posted：2020-09-17 20:27:06
According to the latest information, on September 3, 2020, the official website of National Medical Products Administration showed that Joincare (600380) was approved to produce ipratropium bromide inhalation solution in application of imitated Category IV, which was the first in China to pass the consistency evaluation. Up to now, Joincare has already been approved for production of many kinds of inhalants, such as ipratropium bromide inhalation solution, budesonide suspension for inhalation, compound ipratropium bromide inhalation solution and levalbuterol hydrochloride inhalation solution, which have been considered as evaluated. Among them, levalbuterol hydrochloride inhalation solution fills in the blank domestic market.
More
1
2
3

Quick Navigation

Service Hotline

Service

Hotline

Copyright © Joincare Pharmaceutical Group Industry Co., Ltd. All Rights Reserved.  Powered by：www.300.cn Zhuhai  粤ICP备14024104号